Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Martinot, Jean-Benoît
ABNCoV2-03, NCT05329220 / 2021-005504-36: ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2	Completed	3	4223	Europe, US	ABNCoV2, Comirnaty	Bavarian Nordic	COVID-19 Disease	03/23	10/23
PREPARED-1, NCT06339008: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis	Recruiting	3	450	Europe, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Perennial Allergic Rhinitis (PAR)	10/25	02/27
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)	Recruiting	3	510	Europe, Canada, Japan, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)	10/26	02/27
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD Jan 2024 - Dec 2024: Data from MATINEE trial for COPD Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD	Completed	3	806	Europe, Canada, US, RoW	Placebo, Mepolizumab	GlaxoSmithKline, PPD DEVELOPMENT, LP	Pulmonary Disease, Chronic Obstructive	08/24	08/24
BOREAS, NCT04933383 / 2019-002849-38: Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics	Completed	1/2	23	Europe	AQ001S 0.125 mg/ml, budesonide inhalation solution 0.125 mg/ml, Budesonide 0.125 mg/ml inhalation suspension, Budesonide inhalation suspension 0.125 mg/ml	Aquilon Pharmaceuticals S.A., Walloon Region (SPW-EER)	Asthma	12/22	01/23